ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular disease"

  • Abstract Number: 2164 • 2018 ACR/ARHP Annual Meeting

    IMPACT of a Systematic Screening of Multimorbidities in Patients with Chronic Inflammatory Rheumatic Diseases

    Mégane Beurai-Weber Jr.1, Audrey Jaussent2, Guilhem du Cailar3, Marie-Christine Picot2, François Roubille Sr.4, Jean-David Cohen5, Jacques Morel6, Jean Bousquet7, Pierre Fesler8, Bernard Combe9 and Claire Daien10, 1Rheumatology Department, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, 2Department of medical information, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, 3Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, 4Department of cardiology, Arnaud de Villeneuve Hospital and Montpellier University, MONTPELLIER, France, 5IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France, 6Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, 7MACVIA-France, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, 8Internal medicine and hypertension, Lapeyronie Hospital and Montpellier University, Montpellier, France, 9University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France, 10Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France

    Background/Purpose: EULAR proposes to screen multimorbidities in chronic inflammatory rheumatic diseases. The aim of the study was to assess i) multimorbidities in patients with chronic…
  • Abstract Number: 2859 • 2018 ACR/ARHP Annual Meeting

    Do Preventive Cardiology Consults Versus Usual Care Improve Cardiovascular Risk Factor Assessment and Management in Patients with Rheumatoid Arthritis?

    Ellen Romich1, Haitham Ahmed2, Amy Nowacki3 and M. Elaine Husni4, 1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, 2Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Rheumatology, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Rheumatoid arthritis (RA) patients have around 50% increased risk of cardiovascular disease (CVD). Both traditional and RA-specific cardiovascular (CV) risk factors contribute to the…
  • Abstract Number: 511 • 2018 ACR/ARHP Annual Meeting

    Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers of Inflammation and Atherosclerosis

    Linda F. Wang1, Yaming Li2, Douglas Landsittel3, Suresh R. Mulukutla4, Steven Reis5, Marc Levesque6, Donald M. Jones7, Rachel Gartland6, Jennifer Avolio8, Ali Hakim Shoushtari8, Flordeliza Villanueva5, Larry W. Moreland9 and Kimberly P. Liang6, 1School of Medicine, University of Pittsburgh, Pittsburgh, PA, 2Biostatistics, University of Pittsburgh, Pittsburgh, PA, 3Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 4Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, 5Cardiology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, 9Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Rheumatoid arthritis (RA) patients have an elevated risk of cardiovascular (CV) disease unexplained by traditional CV risk factors. Markers of systemic inflammation, including those…
  • Abstract Number: 872 • 2018 ACR/ARHP Annual Meeting

    Is the Serum Uric Acid Therapeutic Target Protective of Chronic Kidney Disease, Cardiovascular Disease, and Mortality for Patients with Gout? a Longitudinal Study

    Douglas C.A. Taylor1, Dena Jaffe2, Moshe Hoshen3, Galit Shefer3, Asaf Bachrach3, Becca Feldman3, An-Chen Fu1 and Hyon K. Choi4, 1Ironwood Pharmaceuticals, Inc., Cambridge, MA, 2Kantar Health, Tel Aviv, Israel, 3Clalit Research Institute, Tel Aviv, Israel, 4Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA

    Background/Purpose: Many studies have found that serum uric acid (sUA) levels are associated with the incidence of chronic kidney disease (CKD), cardiovascular disease (CVD), and…
  • Abstract Number: 1596 • 2018 ACR/ARHP Annual Meeting

    Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting

    Linh Truong1, Nicole Ridolfi1 and Maida Wong2,3, 1Internal Medicine, University of California, Irvine, Orange, CA, 2Department of Medicine, University of California, Irvine, orange, CA, 3Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA

    Background/Purpose: There is accumulating evidence that shows an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors among the psoriatic arthritis (PsA) population. The aim…
  • Abstract Number: 2171 • 2018 ACR/ARHP Annual Meeting

    A 5-Year National Trend in Acute Myocardial Infarctionamong Hospitalized Patients with Psoriatic Arthritis: Data from National Inpatient Sample

    Shraddha Jatwani1, Karan Chugh2, Karan Jatwani3, Vivek Modi4 and Jasleen Kaur5, 1Department of Internal Medicine, Division of Rheumatology, Henry Ford Allegiance Health, Jackson, MI, 2Division of Pulmonary, Critical Care & Sleep, Wayne State University/Detroit Medical Center, Detroit, MI, 3Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital, New York, NY, 4Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital,, New York, NY, 5Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI

    Background/Purpose: Psoriatic arthritis (PsA) is associated with an increased risk of cardiovascular morbidity and mortality. The increase in cardiovascular risk evaluated in a meta-analysis on…
  • Abstract Number: 2934 • 2018 ACR/ARHP Annual Meeting

    Myocardial Microscopic Fibrosis Assessed By T1 Mapping Sequences on Cardiac Magnetic Resonance Imaging Predicts Cardiac Events in Systemic Sclerosis: Data from a Prospective Cohort Study on 40 Patients

    Benjamin Terrier1, Agnès Dechartres2, Hervé Gouya3, Alexis Régent4, Bertrand Dunogué5, Pascal Cohen6, Alice Berezne7, Claire Le Jeunne8, Paul Legmann3, Olivier Vignaux3 and Luc Mouthon9, 1National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, 2Epidemiology, Hotel Dieu, Paris, France, 3Radiology, Cochin hospital, Paris, France, 4Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, Paris, France, 5Internal Medicine, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 6Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 7Internal Medicine, CH Annecy, Annecy, France, 8Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 9Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France

    Background/Purpose: Studies have shown that myocardial involvement may occur in systemic sclerosis (SSc) and lead to cardiac failure. We showed previously that cardiac magnetic resonance…
  • Abstract Number: 200 • 2018 ACR/ARHP Annual Meeting

    Validation of the Ers-RA Risk Score in a Dutch Population

    Milad Baniaamam1 and Michael Nurmohamed2, 1Department of rheumatology, Amsterdam Rheumatology immunology Center | Reade and VU University Medical Center Amsterdam, Netherlands, Amsterdam, Netherlands, 2Rheumatology, VU University Medical Center, Amsterdam, Netherlands

     Background/Purpose: The most frequent cause of death in patients with chronic rheumatoid arthritis (RA) is of cardiovascular (CV) origin. CV risk prediction scores in the…
  • Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting

    Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study

    Maria Auxiliadora Martin1, Santos Castañeda2, Carlos González-Juanatey3, Fernando Sánchez-Alonso4, María Carmen García-Gómez5, R López-González6, Jesus Babio7, Antonio Juan-Mas8, María P Moreno-Gil9, Olga Sanchez-González10, Montserrat Romera11, Jose A Pinto-Tasende12, Jose A Piqueras13, Dolores Fábregas14, Javier Llorca15 and Miguel Angel González-Gay16, 1Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, 2Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, 3Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, 4Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, 5Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, 6Rheumatology, Complejo Hospitalario de Zamora. Spain, Zamora, Spain, 7Rhaumatology, H General de Cabueñes, Gijon, Spain, 8Division of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, Spain, 9Division of Rheumatology, Hospital San Pedro de Alcántara, Cáceres, Spain, 10Division of Rheumatology, Hospital del Sureste, Madrid, Spain, 11Division of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, 12Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 13Division of Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, 14Division of Rheumatology, Hospital de Barbastro, Huesca, Spain, 15Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, 16School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain

    Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…
  • Abstract Number: 873 • 2018 ACR/ARHP Annual Meeting

    General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout

    Kenneth Saag1, Michael A. Becker2, William B. White3, Andrew Whelton4, Jeffrey Borer5, Philip Gorelick6, Barbara Hunt7, Majin Castillo7 and Lhanoo Gunawardhana7, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Chicago Pritzker School of Medicine, Chicago, IL, 3Cardiology, University of Connecticut School of Medicine, Farmington, CT, 4Johns Hopkins University School of Medicine, Hunt Valley, MD, 5State University of New York Downstate Medical Center, Brooklyn, NY, 6Michigan State University College of Human Medicine, Grand Rapids, MI, 7Takeda Pharmaceuticals International, Deerfield, IL

    Background/Purpose: The cardiovascular (CV) safety study CARES has the longest study duration of any randomized controlled trial in patients (pts) with gout and CV disease.…
  • Abstract Number: 1615 • 2018 ACR/ARHP Annual Meeting

    Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

    Moa Lee1, Rishi J. Desai2, Yinzhu Jin3, Gregory Brill1, Alexis Ogdie4 and Seoyoung C. Kim1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cardiovascular disease is a major comorbidity in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Increasing evidence suggests a potential reduction in the risk…
  • Abstract Number: 2217 • 2018 ACR/ARHP Annual Meeting

    Clinical Characteristics of Early Onset Gout in Outpatient Setting

    Yan Li1, Paramarajan Piranavan1, Devi Sundaresan2 and Robert A. Yood3, 1Internal Medicine, St. Vincent Hospital, Worcester, MA, 2Research, Reliant Medical Group, Worcester, MA, 3Reliant Medical Group, Worcester, MA

     Background/Purpose: There has been an increase in the prevalence of gout over the past two decades, with increasing number of patients presenting at younger age.…
  • Abstract Number: 2964 • 2018 ACR/ARHP Annual Meeting

    Detection of Uric Acid Crystals in the Vasculature of Patients with Gout Using Dual-Energy Computed Tomography

    Sharon Barazani1, WeiWei Chi2, Renata Pyzik3, Adam Jacobi4, Tom O'Donnell5, Zahi Fayad3, Venkatesh Mani3 and Yousaf Ali2, 1Medical School, Icahn School of Medicine at Mount Sinai, New York, NY, 2Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 3Translational and Molecular Imaging Institute (TMII), Icahn School of Medicine at Mount Sinai, New York, NY, 4Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, 5Siemens Healthcare, New York, NY

    Background/Purpose: Many recent studies have shown an association between gout and increased cardiovascular risk, however the mechanism by which this occurs is unclear. Dual-Energy Computed…
  • Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting

    Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease

    Annette de Thurah1,2, Ina Trolle Andersen3, Andreas Bugge Tingaard4, Josephine Therkildsen5, Anders Hammerich Riis3, Morten Böttcher5 and Ellen-Margrethe Hauge6,7, 1Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, 2Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 4Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, 5Cardiology, Regional Hospital of Herning, Herning, Denmark, 6Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 7Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
  • Abstract Number: 513 • 2018 ACR/ARHP Annual Meeting

    Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis

    Malin C Erlandsson1,2, Lovisa Lyngfelt3, Caroline Wasén3, Sofia Töyrä Silfverswärd3, Mitra Nadali1,3, Rille Pullerits1,3,4 and Maria I Bokarewa1, 1Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, 3Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, 4Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

    Background/Purpose: Since low serum IGF1 is generally attributed to inflammation and RA severity, we analyze if serum levels of IGF1 is associated with cardiovascular (CV)…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology